Cited by 871Sepsis Diagnosis and TreatmentAutoimmune and Inflammatory Disorders ResearchInflammation biomarkers and pathways

The DOI matches its Crossref record; 47 of the 48 references it cites were found in a registry or an index.

Interleukin-1 Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage Activation Syndrome: Reanalysis of a Prior Phase III Trial*

Open access

Shakoory, Bita, Carcillo, Joseph A., Chatham, W. Winn, Amdur, Richard L., Zhao, Huaqing, Dinarello, Charles A., Cron, Randall Q., Opal, Steven M.·2016·Critical Care Medicine

DOI 10.1097/ccm.0000000000001402PMC PMC5378312

Open this paper in CoChat — free account

Abstract

OBJECTIVE: To determine the efficacy of anakinra (recombinant interleukin-1 receptor antagonist) in improving 28-day survival in sepsis patients with features of macrophage activation syndrome. Despite equivocal results in sepsis trials, anakinra is effective in treating macrophage activation syndrome, a similar entity with fever, disseminated intravascular coagulation, hepatobiliary dysfunction, cytopenias, and hyperferritinemia. Hence, sepsis patients with macrophage activation syndrome features may benefit from interleukin-1 receptor blockade. DESIGN: Reanalysis of deidentified data from the phase III randomized interleukin-1 receptor antagonist trial in severe sepsis. SETTING: Multicenter study recruiting through 91 centers from 11 countries in Europe and North America. PATIENTS: Sepsis patients with multiorgan dysfunction syndrome and/or shock (original study) were regrouped based on the presence or the absence of concurrent hepatobiliary dysfunction and disseminated intravascular coagulation as features of macrophage activation syndrome. The non-hepatobiliary dysfunction/disseminated intravascular coagulation group included patients with only hepatobiliary dysfunction, only disseminated intravascular coagulation, or neither. INTERVENTION: Treatment with anakinra or placebo. MEASUREMENTS AND MAIN RESULTS: Main outcome was 28-day mortality. Descriptive and comparative statistics were performed. Data were available for 763 adults from the original study cohort, randomized to receive either anakinra or placebo. Concurrent hepatobiliary dysfunction/disseminated intravascular coagulation was noted in 43 patients (5.6% of total; 18-75 years old; 47% women). The 28-day survival was similar in both anakinra and placebo-treated non-hepatobiliary dysfunction/disseminated intravascular coagulation patients (71.4% vs 70.8%; p = 0.88). Treatment with anakinra was associated with significant improvement in the 28-day survival rate in hepatobiliary dysfunction/disseminated intravascular coagulation patients (65.4% anakinra vs 35.3% placebo), with hazard ratio for death 0.28 (0.11-0.71; p = 0.0071) for the treatment group in Cox regression. CONCLUSIONS: In this subgroup analysis, interleukin-1 receptor blockade was associated with significant improvement in survival of patients with sepsis and concurrent hepatobiliary dysfunction/disseminated intravascular coagulation. A prospective randomized trial using features of macrophage activation syndrome for mortality risk stratification should be undertaken to confirm the role of interleukin-1 blockage.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1097/ccm.0000000000001402

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference
Levy, M. M., Fink, M. P., Marshall, J. C., Abraham, E. H., Angus, D. C., Cook, D., Cohen, J., Opal, S. M., Vincent, J., & Ramsay, G. (2003) · Critical Care Medicine · doi:10.1097/01.ccm.0000050454.01978.3b · Cited by 5,976
Self-citation
The Pathophysiology and Treatment of Sepsis
Hotchkiss, R. S., & Karl, I. E. (2003) · New England Journal of Medicine · doi:10.1056/nejmra021333 · Cited by 4,132
An Expanded Definition of the Adult Respiratory Distress Syndrome
Murray, J. F., Matthay, M. A., Luce, J. M., & Flick, M. R. (1988) · American Review of Respiratory Disease · doi:10.1164/ajrccm/138.3.720 · Cited by 2,641
Interleukin-1 in the pathogenesis and treatment of inflammatory diseases
Dinarello, C. A. (2011) · Blood · doi:10.1182/blood-2010-07-273417 · Cited by 2,248
Self-citation
Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases
Dinarello, C. A., Simon, A., & van der Meer, J. W. M. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3800 · Cited by 1,810
Self-citation
Development and Validation of the HScore, a Score for the Diagnosis of Reactive Hemophagocytic Syndrome
Fardet, L., Galicier, L., Lambotte, O., Marzac, C., Aumont, C., Chahwan, D., Coppo, P., & Hejblum, G. (2014) · Arthritis & Rheumatology · doi:10.1002/art.38690 · Cited by 1,508
Interleukin-1 and the Pathogenesis of the Acute-Phase Response
Epstein, F. H., & Dinarello, C. A. (1984) · New England Journal of Medicine · doi:10.1056/nejm198411293112205 · Cited by 1,151
Self-citation
Confirmatory interleukin-1 receptor antagonist trial in severe sepsis
Opal, S. M., Fisher, C. J., Dhainaut, J.-F., Vincent, J., Brase, R., Lowry, S. F., SADOFF, J. C., Slotman, G. J., Levy, H. A., BALK, R. A., et al. (1997) · Critical Care Medicine · doi:10.1097/00003246-199707000-00010 · Cited by 882
Self-citation
Recombinant Human Interleukin 1 Receptor Antagonist in the Treatment of Patients With Sepsis Syndrome: Results From a Randomized, Double-blind, Placebo-Controlled Trial
Fisher, C. J. (1994) · JAMA · doi:10.1001/jama.1994.03510470040032 · Cited by 790
Highly elevated ferritin levels and the diagnosis of hemophagocytic lymphohistiocytosis
Allen, C. E., Yu, X., Kozinetz, C. A., & McClain, K. L. (2007) · Pediatric Blood & Cancer · doi:10.1002/pbc.21423 · Cited by 637

Show all 48 references

Research works printed but not linked: 4

Emmenegger, 2005, Swiss Med Wkly, 135, 299
Behrens, 2007, J Rheumatol, 34, 1133
Behrens, 2006, J Rheumatol, 33, 2081
Marti-Carvajal, 2012, Cochrane Database Syst Rev, 12, CD004388

Sorted by citations

Items 401–500 of 871

Successful treatment of severe COVID-19 with subcutaneous anakinra as a sole treatment
García, A. G., Sánchez, I., Lopes, V. R., Moreno-Arrones, Ó. M., Tortosa-Cabañas, M., Elías-Sáenz, I., & Hernández‐Rodríguez, J. (2020) · Lara D. Veeken · doi:10.1093/rheumatology/keaa318 · Cited by 21
In Silico Prediction of Molecular Targets of Astragaloside IV for Alleviation of COVID-19 Hyperinflammation by Systems Network Pharmacology and Bioinformatic Gene Expression Analysis
Ge, C., & He, Y. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.556984 · Cited by 21
Assessment of the Hemophagocytic Lymphohistiocytosis HScore in Patients With Coronavirus Disease 2019
Clark, K. E. N., Nevin, W. D., Mahungu, T. W., Lachmann, H. J., & Singh, A. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1463 · Cited by 21
Glucocorticoids with low-dose anti-IL1 anakinra rescue in severe non-ICU COVID-19 infection: A cohort study
Borie, R., Savale, L., Dossier, A., Ghosn, J., Taillé, C., Visseaux, B., Jebreen, K., Diallo, A., Tesmoingt, C., Morer, L., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0243961 · Cited by 21
A perspective on the potential detrimental role of inflammation in pig orthotopic heart xenotransplantation
Thompson, C. P., Jagdale, A., Walcott, G. P., Iwase, H., Foote, J. B., Cron, R. Q., Hara, H., Cleveland, D. C., & Cooper, D. K. C. (2021) · Xenotransplantation · doi:10.1111/xen.12687 · Cited by 21
Self-citation
Anti-inflammatory Treatment of Kawasaki Disease: Comparison of Current Guidelines and Perspectives
Buda, P., Friedman-Gruszczyńska, J., & Książyk, J. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.738850 · Cited by 21
Nutraceutical Targeting of Inflammation-Modulating microRNAs in Severe Forms of COVID-19: A Novel Approach to Prevent the Cytokine Storm
Desjarlais, M., Wirth, M., Lahaie, I., Ruknudin, P., Hardy, P., Rivard, A., & Chemtob, S. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.602999 · Cited by 22
Genetic Predisposition and Inflammatory Inhibitors in COVID-19: Where Do We Stand?
Sagris, Μ., Theofilis, P., Antonopoulos, A. S., Oikonomou, E. K., Tsioufis, K., & Tousoulis, D. (2022) · Biomedicines · doi:10.3390/biomedicines10020242 · Cited by 22
Sepsis subtypes and differential treatment response to vitamin C: biological sub-study of the LOVIT trial
Rynne, J., Mosavie, M., Masse, M.-H., Ménard, J., Battista, M., Maslove, D. M., Sorbo, L. D., St-Arnaud, C., D’Aragon, F., Fox‐Robichaud, A., et al. (2025) · Intensive Care Medicine · doi:10.1007/s00134-024-07733-9 · Cited by 20
Unveiling the research advances of sepsis: pathogenesis, precise intervention and clinical perspective
Cheng, L., Cao, Y., Liu, S., Lv, L., Zhang, J., Bao, J., Wang, G., & Xu, P. (2025) · International Journal of Surgery · doi:10.1097/js9.0000000000002668 · Cited by 27
Predictors of steroid non-response and new approaches in severe alcoholic hepatitis
Sarin, S. K., & Sharma, S. (2020) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2020.0196 · Cited by 20
Pragmatic, open-label, single-center, randomized, phase II clinical trial to evaluate the efficacy and safety of methylprednisolone pulses and tacrolimus in patients with severe pneumonia secondary to COVID-19: The TACROVID trial protocol
Solanich, X., Antolí, A., Zamora, N. P., Fanlo‐Maresma, M., Iriarte, A., Mitjavila, F., Capdevila, O., Molina, M., Sabater‐Riera, J., Bas, J., et al. (2021) · Contemporary Clinical Trials Communications · doi:10.1016/j.conctc.2021.100716 · Cited by 20
Hemoperfusion with CytoSorb to Manage Multiorgan Dysfunction in the Spectrum of Hemophagocytic Lymphohistiocytosis Syndrome in Critically Ill Children
Bottari, G., Murciano, M., Merli, P., Bracaglia, C., Guzzo, I., Stoppa, F., Pardeo, M., Nunziata, J., Bufalo, F. D., Genuini, L., et al. (2021) · Blood Purification · doi:10.1159/000517471 · Cited by 20
The potential biomarker TIFA regulates pyroptosis in sepsis-induced acute kidney injury
Li, Y., Zhang, J., Zhai, P., Hu, C., Suo, J., Wang, J., Liu, C., & Peng, Z. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109580 · Cited by 20
Tocilizumab-coated solid lipid nanoparticles loaded with cannabidiol as a novel drug delivery strategy for treating COVID-19: A review
Zielińska, A., Eder, P., Karczewski, J., Szalata, M., Hryhorowicz, S., Wielgus, K., Szalata, M., Dobrowolska, A., Atanasov, A. G., Słomski, R., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1147991 · Cited by 22
Immunomodulatory approaches in managing lung inflammation in COVID‐19: A double‐edge sword
Verma, G., Dhawan, M. K., Saied, A. A., Kaur, G., Kumar, R., & Emran, T. B. (2023) · Immunity Inflammation and Disease · doi:10.1002/iid3.1020 · Cited by 20
Non-conventional immunomodulation in the management of sepsis
Slim, M. A., Turgman, O., van Vught, L. A., van der Poll, T., & Wiersinga, W. J. (2023) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2023.10.032 · Cited by 21
Coronavirus is the trigger, but the immune response is deadly
Cron, R. Q. (2020) · The Lancet Rheumatology · doi:10.1016/s2665-9913(20)30165-x · Cited by 20
Self-citation
IL-1 receptor antagonist in sepsis: new findings with old data?
Grimaldi, D., Turcott, E. W. G., & Taccone, F. S. (2016) · Journal of Thoracic Disease · doi:10.21037/jtd.2016.08.51 · Cited by 20
“What’s new?”
Pickkers, P., & van der Poll, T. (2018) · Intensive Care Medicine · doi:10.1007/s00134-018-5462-8 · Cited by 12
Cytokine storm
Karki, R., Netea, M. G., Diorio, C., & Kanneganti, T. (2026) · Nature Reviews Disease Primers · doi:10.1038/s41572-025-00677-4 · Cited by 24
The Understanding and Management of Organism Toxicity in Septic Shock
Genga, K. R., Shimada, T., Boyd, J. H., Walley, K. R., & Russell, J. A. (2018) · Journal of Innate Immunity · doi:10.1159/000487818 · Cited by 19
Pathogenic implications, incidence, and outcomes of COVID-19 in autoimmune inflammatory joint diseases and autoinflammatory disorders
Ruscitti, P., Conforti, A., Cipriani, P., Giacomelli, R., Tasso, M., Costa, L., & Caso, F. (2021) · Revista Brasileira de Reumatologia · doi:10.1186/s42358-021-00204-5 · Cited by 19
Efficacy and safety of anakinra in adults presenting deteriorating respiratory symptoms from COVID-19: A randomized controlled trial
Audemard‐Verger, A., Gouge, A. L., Pestre, V., Courjon, J., Langlois, V., Vareil, M.-O., Devaux, M., Bienvenu, B., Leroy, V., Goulabchand, R., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0269065 · Cited by 19
Macrophages in the inflammatory response to endotoxic shock
Zhao, X., Wang, M., Zhang, Y., Zhang, Y., Tang, H., Yue, H., Zhang, L., & Song, D. (2024) · Immunity Inflammation and Disease · doi:10.1002/iid3.70027 · Cited by 20
Hämophagozytische Lymphohistiozytose
Lachmann, G., Rosée, P. G. L., Schenk, T., Brunkhorst, F. M., & Spies, C. (2016) · Der Anaesthesist · doi:10.1007/s00101-016-0216-x · Cited by 19
Alcoholic Liver Disease
Mitchell, M. C., & Szabó, G. (2017) · Wiley eBooks · doi:10.1002/9781119251316.ch26 · Cited by 19
Single-cell dynamics of breakthrough toxicities after anakinra prophylaxis for axicabtagene ciloleucel in lymphoma
Frigault, M. J., Yao, N., Berger, T. R., Wehrli, M., Gallagher, K., Horick, N., Graham, C., Jacobson, C. A., Chen, Y., Leick, M. B., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2024015161 · Cited by 21
Treatment of Inflammatory Diseases with IL-1 Blockade
Dinarello, C. A. (2018) · Current Otorhinolaryngology Reports · doi:10.1007/s40136-018-0181-9 · Cited by 18
Self-citation
COVID19-associated cardiomyocyte dysfunction, arrhythmias and the effect of Canakinumab
Dimai, S., Semmler, L., Prabhu, A., Stachelscheid, H., Huettemeister, J., Klaucke, S. C., Lacour, P., Blaschke, F., Kruse, J. M., Parwani, A. S., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0255976 · Cited by 18
Hyperferritinemia Screening to Aid Identification and Differentiation of Patients with Hyperinflammatory Disorders
Carol, H. A., Mayer, A. S., Zhang, M. S., Dang, V., Varghese, J., Martinez, Z., Schneider, C., Baker, J. E., Tsoukas, P., Behrens, E. M., et al. (2024) · Journal of Clinical Immunology · doi:10.1007/s10875-024-01797-4 · Cited by 18
Self-citation
Role of Damage-Associated Molecular Patterns and Uncontrolled Inflammation in Pediatric Sepsis-Induced Multiple Organ Dysfunction Syndrome
Pang, D., Bashir, D. A., Carcillo, J. A., Nguyen, T. C., Aneja, R. K., & Alcamo, A. M. (2018) · Journal of Pediatric Intensive Care · doi:10.1055/s-0038-1675639 · Cited by 18
Self-citation
Prevalence and Outcome of Secondary Hemophagocytic Lymphohistiocytosis Among SIRS Patients: Results from a Prospective Cohort Study
Gualdoni, G. A., Hofmann, G., Wohlfarth, P., Winkler, H., Winkler, S., Haslacher, H., Thalhammer, R., Makristathis, A., Ratzinger, F., & Burgmann, H. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8040541 · Cited by 18
Immune Profiling of COVID-19 in Correlation with SARS and MERS
Khalil, B. A., Shakartalla, S. B., Goel, S., Mdkhana, B., Halwani, R., Maghazachi, A. A., AlSafar, H. S., Al‐Omari, B., & Bataineh, M. T. A. (2022) · Viruses · doi:10.3390/v14010164 · Cited by 18
An Evidence-Based Guideline Improves Outcomes for Patients With Hemophagocytic Lymphohistiocytosis and Macrophage Activation Syndrome
Taylor, M. L., Hoyt, K. J., Han, J. K., Benson, L. A., Case, S., Chandler, M. T., Chang, M. H., Platt, C. D., Cohen, E. M., Day‐Lewis, M., et al. (2022) · The Journal of Rheumatology · doi:10.3899/jrheum.211219 · Cited by 18
Compartmentalization of the inflammatory response during bacterial sepsis and severe COVID-19
Cavaillon, J., Chousterman, B. G., & Skirecki, T. (2024) · Journal of Intensive Medicine · doi:10.1016/j.jointm.2024.01.001 · Cited by 18
Monitoring immunomodulation in patients with sepsis
Kyriazopoulou, E., & Giamarellos‐Bourboulis, E. J. (2020) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2020.1851199 · Cited by 17
High‑dose intravenous immunoglobulins as a therapeutic option in critical illness polyneuropathy accompanying SARS‑CoV‑2 infection: A case‑based review of the literature (Review)
Stoian, A., Bajkó, Z., Maier, S., Cioflinc, R. A., Grigorescu, B. L., Moțățăianu, A., Bărcuţean, L., Bălașa, R., & Stoian, M. (2021) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2021.10616 · Cited by 18
Patterns of Organ Dysfunction in Critically Ill Children Based on PODIUM Criteria
Sanchez-Pinto, L. N., Bembea, M. M., Farris, R. W., Hartman, M. E., Odetola, F. O., Spaeder, M. C., Watson, R. S., Zimmerman, J. J., Bennett, T. D., & Collaborative, P. O. D. I. U. M. (. (2021) · PEDIATRICS · doi:10.1542/peds.2021-052888p · Cited by 18
Anakinra treatment efficacy in reduction of inflammatory biomarkers in COVID‐19 patients: A meta‐analysis
Naveed, Z., Sarwar, M., Ali, Z., Saeed, D., Choudhry, K., Sarfraz, A., Sarfraz, Z., Félix, M., & Chérrez-Ojeda, I. (2022) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.24434 · Cited by 17
Charting the course for improved outcomes in chronic critical illness: therapeutic strategies for persistent inflammation, immunosuppression, and catabolism syndrome (PICS)
Polcz, V. E., Barrios, E. L., Larson, S. D., Efron, P. A., & Rincon, J. C. (2024) · British Journal of Anaesthesia · doi:10.1016/j.bja.2024.05.005 · Cited by 20
Endothelial Cell Dysfunction Due to Molecules Secreted by Macrophages in Sepsis
He, H., Zhang, W., Jiang, L., Tong, X., Zheng, Y., & Xia, Z. (2024) · Biomolecules · doi:10.3390/biom14080980 · Cited by 19
TnI and IL-18 levels are associated with prognosis of sepsis
Wu, Q., Xiao, Z., Pu, Y., Zhou, J., Wang, D., Huang, Z., & Hou, D. (2019) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2018-136371 · Cited by 18
An Atypical Presentation of Fulminant Myocarditis Secondary to COVID-19 Infection
Richard, I., Robinson, B., Dawson, A., Aya, A., & Ali, R. (2020) · Cureus · doi:10.7759/cureus.9179 · Cited by 17
Evaluation of 17 patients with COVID‐19 pneumonia treated with anakinra according to HScore, SOFA, MuLBSTA, and Brescia‐COVID respiratory severity scale (BCRSS) scoring systems
Erden, A., Özdemir, B., Karakaş, Ö., Mutlu, N. M., İzdeş, Ş., Kalem, A. K., Bilir, Y. A., Aypak, A., Akıncı, E., Güner, R., et al. (2020) · Journal of Medical Virology · doi:10.1002/jmv.26473 · Cited by 17
Immune Response Resetting as a Novel Strategy to Overcome SARS-CoV-2–Induced Cytokine Storm
Nowill, A. E., & de Campos-Lima, P. O. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.2000892 · Cited by 17
Plasma Ferritin as Marker of Macrophage Activation-Like Syndrome in Critically Ill Patients With Community-Acquired Pneumonia
Brands, X., de Vries, F. M. C., Uhel, F., Haak, B. W., Sengers, H. P., Schuurman, A. R., van Engelen, T. S. R., Lutter, R., Cremer, O. L., Bonten, M. J. M., et al. (2021) · Critical Care Medicine · doi:10.1097/ccm.0000000000005072 · Cited by 17
Consequences of hemophagocytic lymphohistiocytosis‐like cytokine release syndrome toxicities and concurrent bacteremia
Masih, K. E., Ligon, J. A., Yates, B., Shalabi, H., Little, L., Islam, Z., Ombrello, A. K., Inglefield, J. R., Nussenblatt, V. R., Manion, M. M., et al. (2021) · Pediatric Blood & Cancer · doi:10.1002/pbc.29247 · Cited by 17
Comparative Survival Analysis of Immunomodulatory Therapy for COVID-19 'Cytokine Storm': A Retrospective Observational Cohort StudyPreprint
Narain, S., Stefanov, D. G., Chau, A. S., Weber, A. G., Marder, G. S., Kaplan, B. M., Malhotra, P., Bloom, O., Liu, A., LESSER, M. L., et al. (2020) · SSRN Electronic Journal · doi:10.1101/2020.06.16.20126714 · Cited by 17
Targeting the NLRP3 inflammasome in sepsis: Molecular mechanisms and therapeutic strategies
Ma, Y., Meng, J., Sun, F., & Lei, M. (2025) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2025.09.006 · Cited by 17
Bioinformatics-Based Study to Investigate Potential Differentially Expressed Genes and miRNAs in Pediatric Sepsis
Xie, K., Kong, S., Li, F., Zhang, Y., Wang, J., & Zhao, W. (2020) · Medical Science Monitor · doi:10.12659/msm.923881 · Cited by 16
Advances in pharmacotherapy for acute and recurrent pericarditis
Vecchié, A., Buono, M. G. D., Mauro, A. G., Cremer, P. C., Imazio, M., Klein, A. L., Abbate, A., Dentali, F., & Bonaventura, A. (2022) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2022.2054327 · Cited by 16
Immunotherapy to treat sepsis induced-immunosuppression: Immune eligibility or outcome criteria, a systematic review
Borouchaki, A., de Roquetaillade, C., Barthélémy, R., Mebazaa, A., & Chousterman, B. G. (2022) · Journal of Critical Care · doi:10.1016/j.jcrc.2022.154137 · Cited by 16
IL-6 rs1800795 polymorphism is associated with septic shock-related death in patients who underwent major surgery: a preliminary retrospective study
Jiménez‐Sousa, M. Á., Medrano, L. M., Liu, P., Fernández‐Rodríguez, A., Almansa, R., Gómez‐Sánchez, E., Ortega, A., Heredia‐Rodríguez, M., Gómez‐Pesquera, E., Tamayo, E., et al. (2017) · Annals of Intensive Care · doi:10.1186/s13613-017-0247-8 · Cited by 16
Preparation and Evaluation of IL-1ra-Loaded Dextran/PLGA Microspheres for Inhibiting Periodontal Inflammation In Vitro
Lu, J., Ren, B.-J., Wang, L., Li, M., & Liu, Y. (2019) · Inflammation · doi:10.1007/s10753-019-01107-w · Cited by 16
Coronavirus Desease 2019 (COVID-19) in Children: Lessons from Pediatric Rheumatology
Kaleda, M. I., Никишина, И. П., Fedorov, E. S., & Nasonov, E. L. (2020) · Rheumatology Science and Practice · doi:10.47360/1995-4484-2020-469-479 · Cited by 16
Lessons from pathophysiology: Use of individualized combination treatments with immune interventional agents to tackle severe respiratory failure in patients with COVID-19
Dalekos, G. Ν., Stefos, A., Georgiadou, S. P., Lygoura, V., Michail, A., Ntaios, G., Samakidou, A., Giannoulis, G., Gabeta, S., Vlychou, M., et al. (2021) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2021.03.026 · Cited by 15
Targeting hyperinflammation in infection: can we harness the COVID-19 therapeutics momentum to end the dengue drugs drought?
McBride, A., Mehta, P., Rivino, L., Ramanan, A. V., & Yacoub, S. (2021) · The Lancet Microbe · doi:10.1016/s2666-5247(21)00087-2 · Cited by 16
Anakinra was not associated with lower mortality in hospitalised COVID‐19 patients: A systematic review and meta‐analysis of randomized controlled trials
Shang, W., Zhang, Y., Wang, G., & Han, D. H. (2023) · Reviews in Medical Virology · doi:10.1002/rmv.2418 · Cited by 17
Biological drivers of the host response in sepsis
Wiersinga, W. J., & van der Poll, T. (2025) · Thorax · doi:10.1136/thorax-2024-222012 · Cited by 15
SpyTag-PEGylated probiotics delivering IL-1Ra modulate gut-lung crosstalk to mitigate septic lung injury
Yao, Q., Liu, T., Wen, J., Yang, Q., Li, Y., Huang, Y., Zhang, L., Zhu, B., Tian, Y., Wang, Y., et al. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114163 · Cited by 15
Rationale for Adjunctive Therapies for Pediatric Sepsis Induced Multiple Organ Failure
Podd, B. S., Simon, D. W., Lopez, S. M. C., Nowalk, A. J., Aneja, R. K., & Carcillo, J. A. (2017) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2017.06.007 · Cited by 15
Self-citation
Rhein ameliorates septic lung injury and intervenes in macrophage metabolic reprogramming in the inflammatory state by Sirtuin 1
Wang, W., Wang, Z., Yang, X., Song, W., Chen, P., Gao, Z., Wu, J., & Huang, F. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.121115 · Cited by 15
Intravenous anakinra to curb cytokine storm in adult-onset Still's disease and in macrophage activation syndrome: A case series
Bindoli, S., Galozzi, P., Doria, A., & Sfriso, P. (2023) · Joint Bone Spine · doi:10.1016/j.jbspin.2023.105524 · Cited by 15
From febrile pancytopenia to hemophagocytic lymphohistiocytosis-associated organ dysfunction
Carcillo, J. A., Podd, B. S., & Simon, D. W. (2017) · Intensive Care Medicine · doi:10.1007/s00134-017-4853-6 · Cited by 15
Self-citation
Is it infection or rather vascular inflammation? Game-changer insights and recommendations from patterns of multi-organ involvement and affected subgroups in COVID-19
AbdelMassih, A. F., Kamel, A., Mishriky, F., Ismail, H., Qadi, L. E., Malak, L., El-Husseiny, M., Ashraf, M., Hafez, N., AlShehry, N., et al. (2020) · Cardiovascular Endocrinology & Metabolism · doi:10.1097/xce.0000000000000211 · Cited by 16
Chloroquine and Hydroxychloroquine
Barber, B. E. (2017) · doi:10.1201/9781498747967-175 · Cited by 15
Safety of intravenous anakinra in COVID-19 with evidence of hyperinflammation, a case series
Clark, K. E. N., Collas, O., Lachmann, H. J., Singh, A., Buckley, J., & Bhagani, S. (2020) · Rheumatology Advances in Practice · doi:10.1093/rap/rkaa040 · Cited by 15
Pharmacological treatment of COVID-19: Narrative review of the Working Group in Infectious Diseases and Sepsis (GTEIS) and the Working Groups in Transfusions and Blood Products (GTTH)
Dı́az, E., Menéndez, R. A., Cortés, P. V., Escapa, M. G., Suberviola, B., Lázaro, A. S., Marcos-Neira, P., Quintana‐Díaz, M., & González, M. C. (2021) · Medicina Intensiva (English Edition) · doi:10.1016/j.medine.2020.06.007 · Cited by 15
Rapid and Continuous Simultaneous Monitoring of Interleukin-6 and Lactate Using a Bioelectronic Sensor Platform: toward Early Sepsis Prediction
Nandhakumar, P., Kim, G., Sandhu, S. S., Reynoso, M., Khan, M. I., Raucci, A., He, X., Acot, B., Park, R., Surace, S., et al. (2025) · Analytical Chemistry · doi:10.1021/acs.analchem.5c03473 · Cited by 14
CXCL9 as a novel prognostic marker to identify high-risk adults with hemophagocytic lymphohistiocytosis
Rocco, J. M., Oved, J. H., Patel, R., Herskovits, A. Z., Nair, N., Shakoory, B., Robertson, T., Dileo, R., Jacobs, M. W., Zerbe, C. S., et al. (2025) · Blood · doi:10.1182/blood.2025030976 · Cited by 14
Self-citation
Effects of N-Acetylcysteine Supplementation on Oxidative Stress and Expression of Apoptosis-Related Genes in Testicular Tissue of Rats Exposed to Lead
Bajgiran, F. A., Koohpar, Z. K., & Salehzadeh, A. (2022) · Biological Trace Element Research · doi:10.1007/s12011-022-03325-0 · Cited by 14
Endotoxemic Shock: A Molecular Phenotype in Sepsis
Kellum, J. A., Foster, D., & Walker, P. M. (2022) · The Nephron journals/Nephron journals · doi:10.1159/000525548 · Cited by 15
Immune Profiling Panel Gene Set Identifies Critically Ill Patients With Low Monocyte Human Leukocyte Antigen-DR Expression: Preliminary Results From the REAnimation Low Immune Status Marker (REALISM) Study
Peronnet, E., Blein, S., Venet, F., Cerrato, E., Fleurie, A., Llitjos, J., Kreitmann, L., Terraz, G., Conti, F., Gossez, M., et al. (2023) · Critical Care Medicine · doi:10.1097/ccm.0000000000005832 · Cited by 14
Inflammatory Response and Anti-Inflammatory Treatment in Persistent Inflammation-Immunosuppression-Catabolism Syndrome (PICS)
Xiong, D., Geng, H., Lv, X., Wang, S., & Jia, L. (2025) · Journal of Inflammation Research · doi:10.2147/jir.s504694 · Cited by 15
The Lazarus effect of very high-dose intravenous anakinra in severe non-familial CNS-HLH
Kavirayani, A., Charlesworth, J. E. G., Segal, S., Kelly, D. F., Wilson, S. R., Qureshi, A., Blanco, E., Weitz, J., O'Shea, D., & Bailey, K. M. (2020) · The Lancet Rheumatology · doi:10.1016/s2665-9913(20)30361-1 · Cited by 14
Secondary Hemophagocytic Lymphohistiocytosis and Autoimmune Cytopenias: Case Description and Review of the Literature
Fattizzo, B., Ferraresi, M., Giannotta, J. A., & Barcellini, W. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10040870 · Cited by 14
COVID-19 in Recent Lung Transplant Recipients: Clinical Outcomes and Management Strategies
Zimmermann, J., Glueck, O., Fertmann, J. M., Sienel, W. G. R., Yavuz, G., Damirov, F., Kovács, J., Tufman, A., Irlbeck, M., Kneidinger, N., et al. (2022) · Transplantation Proceedings · doi:10.1016/j.transproceed.2021.12.014 · Cited by 14
Applying Lessons Learned From COVID-19 Therapeutic Trials to Improve Future ALI/ARDS Trials
Wu, Q., Pennini, M. E., Bergmann, J. N., Kozak, M., Herring, K. D., Sciarretta, K. L., & Armstrong, K. L. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac381 · Cited by 14
Anakinra—An Interleukin-1 Receptor Antagonist for COVID-19
Nguyen, T. V., Dima, L., & Willett, K. C. (2023) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001603 · Cited by 15
The rheumatology/hematology interface: CAPS and MAS diagnosis and management
Gansner, J. M., & Berliner, N. (2018) · Hematology · doi:10.1182/asheducation-2018.1.313 · Cited by 14
Hemophagocytic Lymphohistiocytosis in the Emergency Department: Recognizing and Evaluating a Hidden Threat
Morrissette, K. M., Bridwell, R. E., Lentz, S. A., Brem, E. A., Gutierrez, K. O., Singh, M., Koyfman, A., & Long, B. (2021) · Journal of Emergency Medicine · doi:10.1016/j.jemermed.2021.02.006 · Cited by 14
Transcriptomic Profiles in Children With Septic Shock With or Without Immunoparalysis
Snyder, A. D., Jedreski, K., Fitch, J., Wijeratne, S., Wetzel, A. N., Hensley, J., Flowers, M., Bline, K., Hall, M. W., & Muszynski, J. A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.733834 · Cited by 16
American College of Rheumatology Guidance for the Management of Pediatric Rheumatic Disease During the COVID‐19 Pandemic: Version 2
Wahezi, D. M., Lo, M. S., Rubinstein, T. B., Ringold, S., Ardoin, S. P., Downes, K. J., Jones, K. B., Laxer, R. M., Madan, R. P., Mudano, A. S., et al. (2021) · Arthritis & Rheumatology · doi:10.1002/art.41772 · Cited by 17
In Silico Identification of Natural Product-Based Inhibitors Targeting IL-1β/IL-1R Protein–Protein Interface
Liu, T., Chen, Y.-K., Adil, M., Almehmadi, M. M., Alshabrmi, F. M., Allahyani, M. A., Alsaiari, A. A., Liu, P., Khan, M. R., & Peng, Q. (2023) · Molecules · doi:10.3390/molecules28134885 · Cited by 13
COVID-19: A state of art on immunological responses, mutations, and treatment modalities in riposte
Gong, X., Khan, A., Wani, M. Y., Ahmad, A., & Duse, A. G. (2022) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2022.12.019 · Cited by 15
Distinct host-response signatures in circulatory shock: a narrative review
Soussi, S., dos Santos, C. C., Jentzer, J. C., Mebazaa, A., Gayat, É., Pöss, J., Schaubroeck, H., Billia, F., Marshall, J. C., & Lawler, P. R. (2023) · Intensive Care Medicine Experimental · doi:10.1186/s40635-023-00531-5 · Cited by 13
Pharmacological preconditioning with the cellular stress inducer thapsigargin protects against experimental sepsis
Wei, Y., Meng, M., Tian, Z., Xie, F., Yin, Q., Dai, C., Wang, J., Zhang, Q., Liu, Y., Liu, C., et al. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.12.017 · Cited by 13
Immunosuppressive and immunomodulator therapy for rare or uncommon skin disorders in pandemic days
Karadağ, A. S., Kayıran, M. A., Lotti, T., & Wollina, U. (2020) · Dermatologic Therapy · doi:10.1111/dth.13686 · Cited by 13
COVID-19: should we consider it as a septic shock? (The treatment of COVID-19 patients in the ICU)
Roger, C. (2021) · Current Opinion in Anaesthesiology · doi:10.1097/aco.0000000000000956 · Cited by 13
Pharmacological mechanism of immunomodulatory agents for the treatment of severe cases of COVID-19 infection
Bahari, Z., Jangravi, Z., Ghoshooni, H., Afarinesh, M. R., & Meftahi, G. H. (2021) · Inflammation Research · doi:10.1007/s00011-021-01445-2 · Cited by 13
Nanodiamond as a Cytokine Sponge in Infectious Diseases
Yoo, W., Lee, W., Kim, H. N., Jeong, J., Park, H. H., Ahn, J. H., Jung, D., Lee, J., Kim, J.-S., Lee, S. W., et al. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.862495 · Cited by 13
Histiocyte Society blueprint for hemophagocytic lymphohistiocytosis research: deciphering underlying disease mechanisms to optimize diagnosis and therapy
Meyer, L. K., Lee, J. C., Rocco, J. M., & Nichols, K. E. (2025) · Haematologica · doi:10.3324/haematol.2024.286477 · Cited by 14
The endothelial-immunothrombotic storm in viral sepsis: lessons from COVID-19
Zhou, K., Chen, Y., Pang, J., Zhang, J., & Lu, J. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1681764 · Cited by 16
COVID-19 in a liver transplant recipient: Could iatrogenic immunosuppression have prevented severe pneumonia? A case report
Sessa, A., Mazzola, A., Lim, C., Atif, M. M., Pappatella, J., Pourcher, V., Scatton, O., & Conti, F. (2020) · World Journal of Gastroenterology · doi:10.3748/wjg.v26.i44.7076 · Cited by 12
Anakinra in Paediatric Rheumatology and Periodic Fever Clinics: Is the Higher Dose Safe?
Fingerhutová, Š., Jančová, E., & Doležalová, P. (2022) · Frontiers in Pediatrics · doi:10.3389/fped.2022.823847 · Cited by 12
The influence of 4G/5G polymorphism in the plasminogen-activator-inhibitor-1 promoter on COVID-19 severity and endothelial dysfunction
Yatsenko, T., Rios, R. A., Nogueira, T. M., Salama, Y., Takahashi, S., Adachi, E., Tabe, Y., Hattori, N., Osada, T., Naito, T., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1445294 · Cited by 12
Macrophage activation syndrome in Sepsis: from pathogenesis to clinical management
Chen, S., Zhang, C., Luo, J., Lin, Z., Chang, T., Dong, L., Chen, D., & Tang, Z. (2024) · Inflammation Research · doi:10.1007/s00011-024-01957-7 · Cited by 12
Progress on diagnosis and treatment of multisystem inflammatory syndrome in children
Peng, Z., & Zhou, G. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1551122 · Cited by 14
Evaluation of macrophage activation syndrome in hospitalised patients with Kikuchi-Fujimoto disease based on the 2016 EULAR/ACR/PRINTO classification criteria
Ahn, S. S., Lee, B., Kim, D., Jung, S. M., Lee, S., Park, M., Park, Y., Hwang, Y. G., & Song, J. J. (2019) · PLoS ONE · doi:10.1371/journal.pone.0219970 · Cited by 12

Authors: Shakoory, B., Carcillo, J. A., Chatham, W. W., Amdur, R. L., Zhao, H., Dinarello, C. A., Cron, R. Q., & Opal, S. M.
Affiliations: George Washington University (US)
University of Pittsburgh Medical Center (US)
University of Alabama at Birmingham (US)
Temple University (US)
University of Colorado Anschutz (US)
Brown University (US)
ORCID: Shakoory, Bita
Carcillo, Joseph A.
Chatham, W. Winn
Amdur, Richard L.
Zhao, Huaqing
Dinarello, Charles A.
Venue: Critical Care Medicine
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 2016-02
Volume: 44
Issue: 2
Pages: 275-281
ISSN: 0090-3493 (ISSN-L)
DOI: 10.1097/ccm.0000000000001402
PMC: PMC5378312
OpenAlex: W2177407033
Cited by: 867
References: 48
Citations by year: 2026: 66 · 2025: 64 · 2024: 68 · 2023: 76 · 2022: 87 · 2021: 141 · 2020: 226 · 2019: 43 · 2018: 36 · 2017: 42 · 2016: 15
FWCI: 24.58
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Critical Care Medicine (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Institute of General Medical Sciences (R01GM108618)
Topics: Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Sepsis Diagnosis and Treatment
Health Sciences › Medicine › Hematology › Autoimmune and Inflammatory Disorders Research
Life Sciences › Immunology and Microbiology › Immunology › Inflammation biomarkers and pathways
Keywords: sepsis, anakinra, interleukin-1 receptor antagonist, interleukin-1 blockade, 28-day mortality, hepatobiliary dysfunction, disseminated intravascular coagulation, multiple organ failure, septic shock, subgroup analysis, hyperferritinemia, cytokine storm
MeSH terms: Adolescent, Adult, Age Factors, Aged, Aged, 80 and over, Biliary Tract Diseases, Disseminated Intravascular Coagulation, Double-Blind Method, Female, Humans, Liver Diseases, Male, Middle Aged, Multiple Organ Failure, Respiratory Distress Syndrome, Sex Factors, Shock, Septic, Receptors, Interleukin-1, Sepsis, APACHE, Interleukin 1 Receptor Antagonist Protein, Macrophage Activation Syndrome, Young Adult, Acute Kidney Injury

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Interleukin-1 Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage Activation Syndrome: Reanalysis of a Prior Phase III Trial*

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks